RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained a Sector Perform rating on Inovio Pharmaceuticals but has lowered the price target from $8 to $7.
October 04, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Inovio Pharmaceuticals but reduced the price target from $8 to $7, indicating a slightly less optimistic outlook.
The lowering of the price target by RBC Capital suggests a less optimistic view on Inovio's short-term performance, which could lead to a negative impact on the stock price. The maintenance of the Sector Perform rating indicates that the stock is expected to perform in line with the sector, but the reduced price target reflects potential challenges or lower expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100